Our case of myo-pericarditis in a patient on ledipasvir/ sofosbuvir
(LDV/SOF) on the background of known cardiotoxicity of multiple classes
of anti-hepatitis C virus (HCV) direct-acting antivirals (DAATs) raises
the concern of previously-unrecognized adverse effect of LDV/SOF. Our
patient, a 55 year-old male with non-ischemic cardiomyopathy on
HeartWare left ventricular assist device (LVAD) and HCV (genotype 1a)
pursued DAAT for consideration for heart transplant candidacy. Prior to
starting LDV/SOF amiodarone was stopped for 3 months, and blood pressure
and renal function demonstrated stability (creatinine 1.3-1.6 mg/dl, eGFR 50-70 mL/min/1.73m2).
No comments:
Post a Comment